Cargando…

Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial

Detalles Bibliográficos
Autores principales:	Scarfò, Lydia, Ferrari, Silvia, Frustaci, Anna Maria, Tani, Monica, Bari, Alessia, Scarano, Eloise, Colia, Maria, Ranghetti, Pamela, Angelillo, Piera, Ronchi, Paola, Ponzoni, Maurilio, Ferreri, Andrés J. M., Ghia, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631708/ https://www.ncbi.nlm.nih.gov/pubmed/35613463 http://dx.doi.org/10.1182/bloodadvances.2022007138

Ejemplares similares

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2015)

Correction: Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line
por: Agathangelidis, Andreas, et al.
Publicado: (2015)

Establishment and Characterization of PCL12, a Novel CD5(+) Chronic Lymphocytic Leukaemia Cell Line
por: Agathangelidis, Andreas, et al.
Publicado: (2015)

Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models
por: Bianco, Mimma, et al.
Publicado: (2016)

EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine
por: Valsecchi, Roberta, et al.
Publicado: (2020)

Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

Marginal zone lymphoma: Diagnostic challenges among different entities
por: Bongiovanni, Lucia, et al.
Publicado: (2018)

P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
por: Scarfò, Lydia, et al.
Publicado: (2023)

Impfungen unter Ofatumumab gelingen
por: Facharztmagazine, Redaktion
Publicado: (2023)

Toll-like receptor 9 stimulation can induce IκBζ expression and IgM secretion in chronic lymphocytic leukemia cells
por: Fonte, Eleonora, et al.
Publicado: (2017)

Exposure to animals and increased risk of marginal zone B-cell lymphomas of the ocular adnexae
por: Dolcetti, R, et al.
Publicado: (2012)

Ofatumumab treatment in lupus nephritis patients
por: Haarhaus, Malena Loberg, et al.
Publicado: (2016)

P1489: HIGH DOSE IRON IMPAIRS MALIGNANT B-CELL VIABILITY AND IMPROVES IMMUNE ANTITUMOR FUNCTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Bordini, Jessica, et al.
Publicado: (2023)

Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents
por: Barbaglio, Federica, et al.
Publicado: (2020)

P1222: ANTIGEN-INDEPENDENT, CELL-AUTONOMOUS SIGNALING IN SPLENIC MARGINAL ZONE LYMPHOMA
por: Iatrou, Anastasia, et al.
Publicado: (2023)

P1225: CYLD, A NOVEL REGULATOR OF SPLENIC MARGINAL ZONE LYMPHOMA PATHOGENESIS
por: Pseftogkas, Athanasios, et al.
Publicado: (2023)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Infrequent “chronic lymphocytic leukemia-specific” immunoglobulin stereotypes in aged individuals with or without low-count monoclonal B-cell lymphocytosis
por: Agathangelidis, Andreas, et al.
Publicado: (2021)

Role of ofatumumab in treatment of chronic lymphocytic leukemia
por: Veliz, Marays, et al.
Publicado: (2011)

Refractory pemphigus vulgaris successfully treated with ofatumumab
por: Klufas, Daniel M., et al.
Publicado: (2020)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
por: Florou, Despoina, et al.
Publicado: (2020)

Unusual Course of Splenic Marginal Zone Lymphoma
por: Tun, Nay T., et al.
Publicado: (2013)

Unraveling the genetics of transformed splenic marginal zone lymphoma
por: Grau, Marta, et al.
Publicado: (2023)

The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
por: Nabhan, Chadi, et al.
Publicado: (2011)

Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Nutzen der frühzeitigen Behandlung mit Ofatumumab bestätigt
por: Linder, Isabelle
Publicado: (2022)

Current Status in Rechallenge of Immunotherapy
por: Hu, Han, et al.
Publicado: (2023)

Karyometric Comparison of Splenic and Gastric Marginal Zone Lymphomas
por: Styczeń, Magdalena, et al.
Publicado: (2012)

Spontaneous splenic rupture due to marginal zone lymphoma
por: Yepuri, Natesh, et al.
Publicado: (2017)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
por: Laurenti, Luca, et al.
Publicado: (2016)

Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling
por: Payandeh, Zahra, et al.
Publicado: (2018)

Ofatumumab‐associated acute pneumonitis: Not new but still the first case
por: Bonanni, Alice, et al.
Publicado: (2016)

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020)

Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Nutzen der frühzeitigen MS-Behandlung mit Ofatumumab bestätigt
por: Linder, Isabelle
Publicado: (2022)

Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma
por: Ferreri, Andrés J.M., et al.
Publicado: (2022)

Splenic Marginal Zone Lymphoma with Acquired von Willebrand Syndrome Diagnosed via Splenic Bleeding
por: Komeno, Yukiko, et al.
Publicado: (2017)

Discordant lymphoma consisting of splenic mantle cell lymphoma and marginal zone lymphoma involving the bone marrow and peripheral blood: a case report
por: Carulli, Giovanni, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_rb5s7lfbl9eos0tgeo1g645vb7